<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03783754</url>
  </required_header>
  <id_info>
    <org_study_id>TRIDENT MRI</org_study_id>
    <nct_id>NCT03783754</nct_id>
  </id_info>
  <brief_title>Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study</brief_title>
  <acronym>TRIDENT-MRI</acronym>
  <official_title>Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) MRI Sub-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRIDENT Main Study:

      TRIDENT is a multicentre, international, double-blinded, placebo-controlled, parallel-group,
      randomised controlled trial of a fixed low-dose combination BP-lowering pill (&quot;Triple Pill&quot;)
      strategy on top of standard of care, in patients with a history of acute intracerebral
      haemorrhage (ICH) and systolic blood pressure (SBP) levels defined as 'high normal to
      borderline high', and on either minimal or no BP-lowering treatment according to current
      guidelines.

      MRI Sub-Study Centres capable of specific MRI of the brain sequences will be identified. The
      patients in the TRIDENT main study who are identified to be eligible for the MRI Sub-Study
      will undergo MRI scans at baseline (6 weeks to 6 months post-randomisation) and at 36-month
      follow-up time points. All data collected will be analysed centrally at the Brain and Mind
      Centre (BMC) in Sydney, Australia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intracerebral haemorrhage (ICH) is the most serious type of stroke, accounting for 10% of
      stroke in high-income countries and up to 50% in low-to-middle income countries, especially
      in Asia where hypertension is common. ICH in the context of hypertension is often a
      manifestation of underlying cerebral small vessel disease (CSVD).

      In summary, there is a considerable body of evidence supporting and association of CSVD with
      hypertension and poor outcomes, but limited evidence as to whether good BP control can modify
      the natural history of this condition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Main Study: Multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in T2 FLAIR white matter hyperintensities (WMH) volume</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole brain atrophy measured by percentage brain volume change between baseline and 36 months on HIRES-T1.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substructure change - cortical grey matter</measure>
    <time_frame>36 months</time_frame>
    <description>expected range: &gt;400,000 and &lt;800,000mm3 Relevant Sequence: 3D-T1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substructure change - white matter</measure>
    <time_frame>36 months</time_frame>
    <description>expected range: &gt;400,000 and &lt;900,000mm3 Relevant Sequence: 3D-T1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substructure change - cerebrospinal fluid (CSF)</measure>
    <time_frame>36 months</time_frame>
    <description>volume change measured Relevant Sequence: 3D-T1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of cerebral microbleeds (CMBs)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Stroke</condition>
  <condition>Cerebral Small Vessel Diseases</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Vascular Dementia</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Triple Pill (Active Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received via blinded study oral capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg</intervention_name>
    <description>low-dose combination therapy</description>
    <arm_group_label>Triple Pill (Active Treatment)</arm_group_label>
    <other_name>Triple Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eligible for, randomised and continuing in TRIDENT Main Study

          2. No contraindications to MRI scan of the brain

          3. Provide informed consent for the MRI Sub-Study

        Exclusion Criteria:

          1. Any MRI contraindications (e.g. metallic implants, claustrophobia, etc.)

          2. Less than 6 weeks or greater than 6 months post-randomisation (however, where possible
             the baseline MRI Sub-Study scan should be conducted as soon as possible after the
             qualifying ICH. e.g. if the qualifying ICH was 4 months prior to randomisation, the
             baseline scan should be done as close to 6 weeks post-randomisation as possible)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Anderson, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Freed</last_name>
    <phone>+61 2 8052 4522</phone>
    <email>rfreed@georgeinstitute.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Miller</last_name>
      <email>Megan.Miller1@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Dennis Cordato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wade Skoien</last_name>
      <email>wade.skoien@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Rohan Grimley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Jackson</last_name>
      <email>David.Jackson@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Nawaf Yassi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

